Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Visiox and Ocuvex Merge to Form Ophthalmic Powerhouse | Contract Pharma

What are you searching for?

Sign in
Breaking News

Visiox and Ocuvex Merge to Form Ophthalmic Powerhouse

Aim to emerge as a leader in the eye care sector with a strong portfolio of ophthalmic medicines.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Visiox Pharmaceuticals Inc. has entered into a definitive merger agreement with Ocuvex Therapeutics Inc., a privately held ophthalmic pharmaceutical company that boasts a robust pipeline of near-term ophthalmic medicines.
 
The strategic combination aims to position the newly combined entity as an emerging leader in the eye care sector with a strong portfolio of ophthalmic medicines.
 
Visiox’s products, including OMLONTI (omidenepag isopropyl ophthalmic solution), PDP-716 (brimonidine) 0.35%, and SDN-037 (difluprednate) 0.04%, will grow Ocuvex’s market presence and accelerate the commercialization of these promising therapeutics. Going forward, the company will operate under the Ocuvex name, building on Visiox’s commitment to disrupting the ophthalmic market through high-level collaboration with eye care professionals.
 
“The combination of Visiox and Ocuvex makes for a perfect match,” said Ryan S. Bleeks, CEO of Visiox. “We have reached significant milestones with our products and Ocuvex is in a great position to take these advancements forward and bring them to market faster and emerge as a future leader in eye care.”

More Pharma Mergers & Acquisitions

Read Contract Pharma’s 2024 Pharmaceutical Industry Mergers & Acquisitions Roundup.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics